Antibody-drug conjugate · Cytotoxic, directed at ADAM9
Phase 1/2Most advanced trial (none active)
1Registered trials
What is Izeltabart Tapatansine?
Izeltabart tapatansine is an antibody-drug conjugate in which a humanized anti-ADAM9 monoclonal antibody is linked to the maytansinoid DM21, a microtubule-disrupting payload. After binding ADAM9 on tumor cells and being internalized, the payload is released and disrupts microtubule dynamics. It is studied in advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.